CurrentNeighborhood Health Plan of Rhode IslandPolicy 3100-A

Valganciclovir (Valcyte) coverage criteria for cytomegalovirus (CMV)-related indications

Coverage criteria for valganciclovir (Valcyte) including FDA-approved and compendial uses for treatment and prevention of cytomegalovirus (CMV) in members of Neighborhood Health Plan of Rhode Island; applies when approval criteria and no exclusions to therapy are met.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyValganciclovir (Valcyte) coverage criteria for cytomegalovirus (CMV)-related indications

Policy CodePolicy 3100-A

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain authorization and document the specific indication and relevant risk factors (for example donor/recipient CMV serostatus or transplant type/timing) to support coverage for up to 12 months when criteria are met.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12Typical authorization duration granted

3FDA-approved indication groups listed

5+Compendial/other supported uses explicitly listed

Valganciclovir Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

FDA-approved indications (covered when all approval criteria are met)

Authorization of valganciclovir may be granted for these FDA-approved indications for up to 12 months when approval criteria are met:

ANY of the following

Treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS)
Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant adult patients at high risk (donor CMV seropositive/recipient CMV seronegative [D+/R-])
Prevention of CMV disease in kidney transplant patients (4 months to 16 years) and heart transplant patients (1 month to 16 years) at high risk

Compendial uses (covered when all approval criteria are met)

The following compendial/other uses are considered covered when approval criteria are met:

ANY of the following

Prevention of CMV infection in post solid organ transplant or post hematopoietic stem cell transplant (HSCT) — prophylaxis or preemptive treatment
Treatment of CMV infection in solid organ transplant recipients (mild to moderate infection)
Symptomatic congenital CMV infection
Treatment of CMV gastrointestinal disease and pneumonitis in HIV-infected patients
Multicentric Castleman disease (MCD) in human herpesvirus-8 positive members

Authorization duration and reauthorization

Authorization rules described in policy:

ALL of the following

Initial and reauthorization approvals may be granted for up to 12 months for the listed indications
For symptomatic congenital CMV infection, authorization of 12 months total may be granted; reauthorization allowed when prior therapy < 12 months
Authorization duration threshold: 12 months
Reauthorization for other indications may be granted for 12 months when member meets coverage requirements

Authorization and Documentation Requirements

Prior Authorization

Authorization required per indication

Authorization must be obtained and will generally be granted for up to 12 months when the member meets the listed FDA-approved or compendial indication and has no exclusions to therapy.

Documentation Required

Support indication and transplant risk status

Providers should document the specific indication and relevant transplant risk factors to support coverage.

Specific indication (e.g., CMV retinitis, prophylaxis post‑transplant, symptomatic congenital CMV)
Donor/recipient CMV serostatus (D+/R-)
Transplant type (solid organ vs HSCT) and timing relative to prophylaxis or treatment

Clinical Background

Valganciclovir (Valcyte) is an antiviral agent used for the treatment and prevention of cytomegalovirus (CMV) disease, particularly in immunocompromised populations such as patients with HIV/AIDS and recipients of solid organ or hematopoietic stem cell transplants. The product listing in this policy includes both brand and generic formulations and all dosage forms and strengths of valganciclovir (Valcyte).

Coverage under this policy aligns with FDA-approved indications and recognized compendia and guideline-based uses. FDA-approved indications covered when approval criteria are met include: treatment of CMV retinitis in adults with AIDS; prevention of CMV disease in adult kidney, heart, and kidney–pancreas transplant recipients at high risk (donor CMV seropositive/recipient CMV seronegative, D+/R-); and prevention of CMV disease in pediatric kidney and heart transplant recipients within the specified age ranges.

In addition to FDA indications, the policy supports compendial and guideline-based uses when approval criteria are satisfied. These include prophylaxis or preemptive treatment to prevent CMV after solid organ transplant or hematopoietic stem cell transplant (HSCT), treatment of CMV infection in solid organ transplant recipients (mild to moderate disease), treatment of symptomatic congenital CMV infection, treatment of CMV gastrointestinal disease and pneumonitis in people with HIV, and treatment of human herpesvirus‑8–positive multicentric Castleman disease.

Authorization practices reflect these indications: when approval criteria are met and there are no exclusions to therapy, authorizations may generally be granted for up to 12 months (including for induction or maintenance treatment of CMV retinitis in HIV, prevention after transplant [prophylaxis or preemptive treatment], treatment of transplant-associated CMV infection, symptomatic congenital CMV, and MCD in HHV‑8–positive members). For symptomatic congenital CMV, a total of 12 months of therapy may be authorized and reauthorization is allowed when prior therapy has been less than 12 months.